Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 10pembrolizumab 7Cisplatin 7Oxaliplatin 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3fludarabine 2Specimen Handling 2Radiation 2Ipilimumab 2Drug Therapy 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trametinib 1tivozanib 1tislelizumab 1silmitasertib 1pertuzumab 1peposertib 1pemigatinib 1olutasidenib 1lenvatinib 1inositol trispyrophosphate 1futibatinib 1enasidenib 1devimistat 1derazantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cholangiocarcinoma × KP 1339 × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡